The efficacy and safety of using low-dose cyclophosphamide, fludarabine and thymoglobulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent non-severe aplastic anemia：a retrospective study.
Retrospective analysis indicates low-dose cyclophosphamide reduces adverse reactions in patients with aplastic anemia after hematopoietic stem cell transplantation.
Key Points
Successful engraftment occurred in all 31 patients, confirming the effectiveness of the treatment protocol.
Adverse reactions were minimal, with no patients developing severe cardiac or liver toxicity during the follow-up period.
Analysis included data from patients aged 4-46 years, highlighting a diverse patient demographic for this treatment.
Overall survival was high at 95%, suggesting that low-dose cyclophosphamide is a promising option for treating transfusion-dependent non-severe aplastic anemia.